Trial Profile
A Study of Combined Treatment of Apatinib With Docetaxel as Post Second-line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results (n=14, data cut off: Jun1, 2018) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 02 Feb 2018 New trial record